CCCC C4 THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, C4 THERAPEUTICS INC reported revenue of $6.64M (up 2.8% from a year earlier), net income of −$23.6M and diluted EPS of −$0.18; over the last four quarters revenue was $35.0M and net income −$101M; for the fiscal year ended December 2025 revenue was $35.9M, up 1.0% on the year before.

CCCC annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $35.9M, gross profit n/a, operating income −$115M, net income −$105M (margin -292.1%), EPS −$1.27
• Fiscal year ended Dec 2024: revenue $35.6M, gross profit n/a, operating income −$120M, net income −$105M (margin -296.0%), EPS −$1.52
• Fiscal year ended Dec 2023: revenue $20.8M, gross profit n/a, operating income −$139M, net income −$132M (margin -638.3%), EPS −$2.67
• Fiscal year ended Dec 2022: revenue $31.1M, gross profit n/a, operating income −$130M, net income −$128M (margin -412.2%), EPS −$2.62
• Fiscal year ended Dec 2021: revenue $45.8M, gross profit n/a, operating income −$82.1M, net income −$83.9M (margin -183.2%), EPS −$1.82

CCCC quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $6.64M (up 2.8% year over year), net income −$23.6M, EPS −$0.18
• Quarter ended Mar 31, 2026: revenue $6.15M (down 15.0% year over year), net income −$25.1M, EPS −$0.20
• Quarter ended Dec 31, 2025 (from the annual report): revenue $11.0M (up 112.8% year over year), net income −$20.5M, EPS −$0.09
• Quarter ended Sep 30, 2025: revenue $11.2M (down 26.9% year over year), net income −$32.2M, EPS −$0.44
• Quarter ended Jun 30, 2025: revenue $6.46M (down 46.2% year over year), net income −$26.0M, EPS −$0.37
• Quarter ended Mar 31, 2025: revenue $7.24M (up 138.2% year over year), net income −$26.3M, EPS −$0.37
• Quarter ended Dec 31, 2024 (from the annual report): revenue $5.18M (up 58.8% year over year), net income −$34.6M, EPS −$0.50
• Quarter ended Sep 30, 2024: revenue $15.4M (up 38.7% year over year), net income −$24.7M, EPS −$0.35
• Quarter ended Jun 30, 2024: revenue $12.0M (up 350.7% year over year), net income −$17.7M, EPS −$0.26
• Quarter ended Mar 31, 2024: revenue $3.04M (down 19.2% year over year), net income −$28.4M, EPS −$0.41
• Quarter ended Dec 31, 2023 (from the annual report): revenue $3.26M (up 14.3% year over year), net income −$34.8M, EPS −$0.68
• Quarter ended Sep 30, 2023: revenue $11.1M (up 63.9% year over year), net income −$27.0M, EPS −$0.55
• Quarter ended Jun 30, 2023: revenue $2.66M (down 80.7% year over year), net income −$35.9M, EPS −$0.73
• Quarter ended Mar 31, 2023: revenue $3.76M (down 50.9% year over year), net income −$34.8M, EPS −$0.71
• Quarter ended Dec 31, 2022 (from the annual report): revenue $2.85M, net income −$37.2M, EPS −$0.76
• Quarter ended Sep 30, 2022: revenue $6.75M (down 20.5% year over year), net income −$32.0M, EPS −$0.65
• Quarter ended Jun 30, 2022: revenue $13.8M (up 41.4% year over year), net income −$27.4M, EPS −$0.56
• Quarter ended Mar 31, 2022: revenue $7.65M, net income −$31.6M, EPS −$0.65
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$15.7M, EPS −$0.31
• Quarter ended Sep 30, 2021: revenue $8.50M, net income −$24.7M, EPS −$0.51

CCCC cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$98.7M, share buybacks $193K
• Fiscal year ended Dec 2024: operating cash flow −$65.2M, share buybacks $194K
• Fiscal year ended Dec 2023: operating cash flow −$107M, share buybacks $110K
• Fiscal year ended Dec 2022: operating cash flow −$106M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow −$87.0M, share buybacks n/a

CCCC balance sheet

• Jun 30, 2026: cash $78.6M, total assets $359M, total liabilities $112M, shareholders' equity $247M
• Mar 31, 2026: cash $61.3M, total assets $329M, total liabilities $94.6M, shareholders' equity $234M
• Dec 31, 2025: cash $74.6M, total assets $359M, total liabilities $102M, shareholders' equity $257M
• Sep 30, 2025: cash $58.8M, total assets $265M, total liabilities $111M, shareholders' equity $154M
• Jun 30, 2025: cash $78.2M, total assets $297M, total liabilities $122M, shareholders' equity $174M
• Mar 31, 2025: cash $51.3M, total assets $320M, total liabilities $124M, shareholders' equity $195M
• Dec 31, 2024: cash $55.5M, total assets $350M, total liabilities $134M, shareholders' equity $216M
• Sep 30, 2024: cash $59.6M, total assets $376M, total liabilities $133M, shareholders' equity $243M

What is CCCC's revenue?

C4 THERAPEUTICS INC reported $35.0M of revenue over its last four quarters, through June 30, 2026.

Is CCCC profitable?

No. C4 THERAPEUTICS INC lost $101M over the last four quarters.

What is CCCC's EPS?

Diluted earnings per share over the last four quarters were −$0.91; −$0.18 in the latest quarter.

CCCC ownership and insider trades · All stocks